Navigation Links
Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention

Study results from two research papers have shown that use of the drug Ospemifene in combination with other anti-estrogens for vaginal atrophy reduces the incidence of breast cancer. // The study has been proved in mouse model and researchers are planning for a clinical trial.

DeGregorio and his colleagues at UC Davis compared the ability of ospemifene, tamoxifen and raloxifen to inhibit breast cancer in mice exposed to a carcinogen. Ospemifene and tamoxifen both inhibited breast cancer development. Results show that the mice in the ospemifene group were 95 percent less likely than mice in the control group to develop breast cancer and the study result is to be published in the Journal of Steroid Biochemistry and Molecular Biology.

The second study in which the first study author DeGregorio is also a co-author was led by Jeffrey P. Gregg, Associate professor of pathology and laboratory medicine at UC Davis, where they reported that Tamoxifen and Ospemifene both inhibited the growth and progression of pre-malignant breast lesions that closely resemble human ductal carcinomas in situ in mouse model.

Ospemifene is a Selective Estrogen Receptor Modulator (SERM), and is an effective anti-estrogen like tamoxifen and raloxifen which is used in the prevention and treatment of breast cancer which binds to estrogens. Ospemifene is now being developed by QuatRx Pharmaceuticals, an Ann Arbor, Mich.-based biopharmaceutical company that recently merged with Hormos Medical Corp. The drug is expected to enter Phase 3 clinical testing in the United States early next year for the treatment of vaginal atrophy, a common condition among postmenopausal women.

The advantage of Ospemifene over tamoxifen and raloxifen is due to its reduced side effects as raloxifen can cause hot flashes, insomnia and blood clots. Tamoxifen can cause endometrial cancer in patients undergoing tamoxifen therapy for breast cancer. But ospemifene have a unique estrogen-l ike effect on the vagina, yet a neutral effect on the endometrium, or lining of the uterus, and no aggravation or initiation of hot flashes.
'"/>




Related medicine news :

1. Vaginal Birth After C-section Dangerous For Both Mother And Baby
2. PET Scanner detects more Vaginal cancer than CT scans
3. Vaginal Vaccine may prevent periodic infections
4. Increased Risk Of HIV Transmission Following Vaginal Washing
5. Risk Of AIDS Rises With Vaginal Washes
6. Vaginal massage during pregnancy avoids Episiotomy procedure
7. Vaginal Gel That Protects Against HIV To Hit The Markets By 2010
8. Vaginal Delivery Should Be an Option after Multiple Cesareans
9. New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery
10. Extra Vaginal Bleed After ‘C’ Section Can be Prevented By Contraceptive Pils
11. Risk of Hemorrhage Increased in Vaginally Born Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: